Journal of Gynecologic Oncology最新文献_第10页

ATF1 regulates MAL2 expression through inhibition of miR-630 to mediate the EMT process that promotes cervical cancer cell development and metastasis. ATF1 通过抑制 miR-630 来调节 MAL2 的表达，从而介导促进宫颈癌细胞发育和转移的 EMT 过程。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2025-01-01 Epub Date: 2024-07-02 DOI: 10.3802/jgo.2025.36.e11

Yanming Cao, Yuping Peng, Youqun Tang

{"title":"ATF1 regulates MAL2 expression through inhibition of miR-630 to mediate the EMT process that promotes cervical cancer cell development and metastasis.","authors":"Yanming Cao, Yuping Peng, Youqun Tang","doi":"10.3802/jgo.2025.36.e11","DOIUrl":"10.3802/jgo.2025.36.e11","url":null,"abstract":"Objective: The existence of activating transcription factor 1 (ATF1) could be employed as a clinical marker in the context of cervical cancer development, although its specific mechanism has not been fully clarified.Methods: To evaluate the presence of ATF1, miR-630, and myelin and lymphocyte protein 2 (MAL2) in cervical malignancies, we conducted quantitative reverse transcription polymerase chain reaction, immunohistochemistry, and Western blot assays; further studied the expansion, migration, invasion and epithelial-mesenchymal transition (EMT) of cervical carcinoma cells using colony formation assay, transwell, loss cytometry, Western blot. Chromatin immunoprecipitation (ChIP) and RNA immunoprecipitation (RIP) were used to verify that ATF1 could directly transcriptionally repress miR-630; dual luciferase reporter assay and RIP assay were employed to confirm that miR-630 targeted to repress MAL2.Results: In cervical cancer cases, elevated ATF1 expression and reduced miR-630 expression were detected, displaying a negative relationship between them. Inhibition of ATF1 hindered the growth, migration, infiltration, and EMT in cervical carcinoma cells, while upregulation of miR-630 mitigated the aggressive characteristics of these cells. ATF1 was found to transcriptionally repress miR-630 by TransmiR and ALGGEN prediction and ChIP validation. MicroRNA modulates gene expression and affects cancer progression, and we discovered that miR-630 regulates cancer progression by targeting and inhibiting MAL2.Conclusion: ATF1, which modulates the miR-630/MAL2 pathway, affects the EMT process and cervical carcinoma cell growth and spread. Therefore, ATF1 may serve as a promising marker and treatment target for cervical malignancies intervention.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e11"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical practice guidelines for uterine corpus cancer: an update to the Korean Society of Gynecologic Oncology guidelines. 子宫体癌的临床实践指南：韩国妇科肿瘤学会指南的更新。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2025-01-01 DOI: 10.3802/jgo.2025.36.e71

Woo Yeon Hwang, Ju-Hyun Kim, Joseph J Noh, Min-Hyun Baek, Min Chul Choi, Yong Jae Lee, Maria Lee, Dong Hoon Suh, Yong Beom Kim, Dae-Yeon Kim

{"title":"Clinical practice guidelines for uterine corpus cancer: an update to the Korean Society of Gynecologic Oncology guidelines.","authors":"Woo Yeon Hwang, Ju-Hyun Kim, Joseph J Noh, Min-Hyun Baek, Min Chul Choi, Yong Jae Lee, Maria Lee, Dong Hoon Suh, Yong Beom Kim, Dae-Yeon Kim","doi":"10.3802/jgo.2025.36.e71","DOIUrl":"10.3802/jgo.2025.36.e71","url":null,"abstract":"The Korean Society of Gynecologic Oncology has updated its clinical practice guidelines for endometrial cancer to incorporate advancements in recent high-quality randomized controlled trials. These guidelines address evolving treatment paradigms, and are tailored to the Korean medical context. Key updates include a strong recommendation for doxorubicin/trabectedin combination therapy in metastatic or recurrent unresectable leiomyosarcoma based on the significant survival benefits demonstrated in a randomized controlled trial. For advanced or recurrent endometrial cancer, immune checkpoint inhibitors combined with chemotherapy have received strong recommendations, owing to their proven efficacy and increased accessibility in Korea. Conditional recommendations were made for combination therapies involving durvalumab and olaparib, reflecting their potential benefits, but acknowledging regulatory and accessibility constraints. These guidelines aim to provide evidence-based, practical strategies to optimize care for patients with endometrial cancer while addressing unmet clinical needs and adapting global advancements to Korea's healthcare environment.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":"36 1","pages":"e71"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CHIPOR, HORSE, and beyond: unraveling the role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. CHIPOR， HORSE及其他：揭示腹腔热化疗（HIPEC）在卵巢癌中的作用。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2025-01-01 DOI: 10.3802/jgo.2025.36.e73

Myong Cheol Lim

引用次数: 0

Prophylactic salpingectomy as a preventative strategy for ovarian cancer in the general population: a systematic review and meta-analysis. 在普通人群中，预防性输卵管切除术作为卵巢癌的预防策略：一项系统回顾和荟萃分析。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2025-01-01 DOI: 10.3802/jgo.2025.36.e8

Yuting Tang, Haiying Sun, Peiying Fu, Ting Zhou, Ronghua Liu

{"title":"Prophylactic salpingectomy as a preventative strategy for ovarian cancer in the general population: a systematic review and meta-analysis.","authors":"Yuting Tang, Haiying Sun, Peiying Fu, Ting Zhou, Ronghua Liu","doi":"10.3802/jgo.2025.36.e8","DOIUrl":"10.3802/jgo.2025.36.e8","url":null,"abstract":"Objective: The impact of prophylactic salpingectomy on the prevention of epithelial ovarian cancer (EOC) remains unclear, particularly in Asian populations where data is lacking. In this systematic review and meta-analysis study, we sought to assess whether prophylactic salpingectomy could reduce the incidence of ovarian cancer in the general population of multiple ethnicities.Methods: A systematic review and meta-analysis were conducted using PubMed/MEDLINE, EMBASE, the Cochrane Library, and Web of Science to assess the effectiveness of salpingectomy, bilateral salpingectomy (BS), and unilateral salpingectomy (US) in reducing the risk of EOC and evaluating postoperative outcomes.Results: The final analyses included 6 eligible trials (5,747,056 patients), including 1 cohort study and 5 case-control studies. The analyses of these studies demonstrated that women who underwent salpingectomy had a significantly reduced risk of EOC compared to those who did not receive salpingectomy (odds ratio [OR]=0.63; 95% confidence interval [CI]=0.45-0.89; p=0.007). Five studies (5,746,469 patients) indicated a significant reduction in EOC risk among patients who underwent BS (OR=0.48; 95% CI=0.33-0.69; p<0.001). On the other hand, in the analysis of 4 studies (5,745,887 patients) that examined US, the association with EOC risk was not significant despite the protective trend (OR=0.82; 95% CI=0.64-1.06; p=0.12).Conclusion: Our results indicate BS is an effective strategy for reducing the risk of sporadic EOC, but the results did not lead to the same conclusion for patients who underwent US. When a candidate or patient is undergoing a hysterectomy or has other benign diseases, prophylactic BS may be a safe surgical procedure that carries future benefits in terms of EOC risk.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":"36 1","pages":"e8"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models. 在高级别浆液性卵巢癌 PDX 模型中对选择性糖皮质激素受体调节的研究

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2025-01-01 Epub Date: 2024-06-14 DOI: 10.3802/jgo.2025.36.e4

Manisha Taya, Xiaonan Hou, Jennifer T Veneris, Nina Kazi, Melissa C Larson, Matthew J Maurer, Ethan P Heinzen, Hao Chen, Ricardo Lastra, Ann L Oberg, S John Weroha, Gini F Fleming, Suzanne D Conzen

{"title":"Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models.","authors":"Manisha Taya, Xiaonan Hou, Jennifer T Veneris, Nina Kazi, Melissa C Larson, Matthew J Maurer, Ethan P Heinzen, Hao Chen, Ricardo Lastra, Ann L Oberg, S John Weroha, Gini F Fleming, Suzanne D Conzen","doi":"10.3802/jgo.2025.36.e4","DOIUrl":"10.3802/jgo.2025.36.e4","url":null,"abstract":"Objective: In ovarian cancer (OvCa), tumor cell high glucocorticoid receptor (GR) has been associated with poor patient prognosis. In vitro, GR activation inhibits chemotherapy-induced OvCa cell death in association with transcriptional upregulation of genes encoding anti-apoptotic proteins. A recent randomized phase II study demonstrated improvement in progression-free survival (PFS) for heavily pre-treated OvCa patients randomized to receive therapy with a selective GR modulator (SGRM) plus chemotherapy compared to chemotherapy alone. We hypothesized that SGRM therapy would improve carboplatin response in OvCa patient-derived xenograft (PDX).Methods: Six high-grade serous (HGS) OvCa PDX models expressing GR mRNA (NR3C1) and protein were treated with chemotherapy +/- SGRM. Tumor size was measured longitudinally by peritoneal transcutaneous ultrasonography.Results: One of the 6 GR-positive PDX models showed a significant improvement in PFS with the addition of a SGRM. Interestingly, the single model with an improved PFS was least carboplatin sensitive. Possible explanations for the modest SGRM activity include the high carboplatin sensitivity of 5 of the PDX tumors and the potential that SGRMs activate the tumor invasive immune cells in patients (absent from immunocompromised mice). The level of tumor GR protein expression alone appears insufficient for predicting SGRM response.Conclusion: The significant improvement in PFS shown in 1 of the 6 models after treatment with a SGRM plus chemotherapy underscores the need to determine predictive biomarkers for SGRM therapy in HGS OvCa and to better identify patient subgroups that are most likely to benefit from adding GR modulation to chemotherapy.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e4"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of postoperative adjuvant platinum-based chemotherapy and no further therapy after radical surgery in intermediate-risk early-stage cervical cancer. 中危早期宫颈癌术后铂类辅助化疗与根治术后不再治疗的比较。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2025-01-01 Epub Date: 2024-05-01 DOI: 10.3802/jgo.2025.36.e2

Hiroki Nishimura, Tsukuru Amano, Yutaka Yoneoka, Shunichiro Tsuji, Yukiko Taga, Megumi Aki, Masaya Uno, Suzuko Moritani, Ryusuke Murakami, Tomoyasu Kato, Takashi Murakami

{"title":"Comparison of postoperative adjuvant platinum-based chemotherapy and no further therapy after radical surgery in intermediate-risk early-stage cervical cancer.","authors":"Hiroki Nishimura, Tsukuru Amano, Yutaka Yoneoka, Shunichiro Tsuji, Yukiko Taga, Megumi Aki, Masaya Uno, Suzuko Moritani, Ryusuke Murakami, Tomoyasu Kato, Takashi Murakami","doi":"10.3802/jgo.2025.36.e2","DOIUrl":"10.3802/jgo.2025.36.e2","url":null,"abstract":"Objective: To identify a relatively high-risk population in postoperative intermediate-risk cervical cancer and evaluate the effect of platinum-based adjuvant chemotherapy (CT).Methods: We retrospectively reviewed the medical records of patients with stage IA2-IIA cervical cancer who had been treated with radical hysterectomy and pelvic lymphadenectomy and classified as the intermediate-risk group for recurrence by postoperative pathological examination from January 2007 to December 2018 at 3 medical centers in Japan. First, patients with intermediate-risk were stratified by histological type and the number of intermediate-risk factors (IRF; large tumor diameter, lymph vascular space invasion, and deep cervical stromal invasion) and then divided into 2 groups: high and low-risk population (estimated 5-year recurrence-free survival [RFS] rate with no further therapy [NFT] <90% and ≥90%, respectively). Second, the efficacy of CT for the high-risk population was evaluated by comparing RFS and overall survival (OS) between the patients receiving CT and those with NFT.Results: In total, 133 patients were included in the analysis. Among patients with squamous cell carcinoma (SCC) with all IRF or those with non-SCC with 2 to 3 IRF, the 5-year estimated RFS was <90% when treated with NFT. In this population, adjuvant CT was significantly superior to NFT regarding RFS (log-rank, p=0.014), although there was no statistical difference in OS.Conclusion: Patients with SCC with all 3 IRFs and those with non-SCC with 2 to 3 IRFs were at high risk for recurrence. Adjuvant CT is a valid treatment option for these populations.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e2"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical practice guidelines for cervical cancer: an update of the Korean Society of Gynecologic Oncology Guidelines. 宫颈癌临床实践指南：韩国妇科肿瘤学会指南的更新。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2025-01-01 DOI: 10.3802/jgo.2025.36.e70

Ji Geun Yoo, Sung Jong Lee, Eun Ji Nam, Jae Hong No, Jeong Yeol Park, Jae Yun Song, So-Jin Shin, Bo Seong Yun, Sung Taek Park, San-Hui Lee, Dong Hoon Suh, Yong Beom Kim, Keun Ho Lee

引用次数: 0

Airborne and surface contamination after rotational intraperitoneal pressurized aerosol chemotherapy using cisplatin. 使用顺铂进行旋转腹腔内加压气溶胶化疗后的空气和表面污染。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2025-01-01 Epub Date: 2024-06-05 DOI: 10.3802/jgo.2025.36.e12

Wongeon Jung, Mijin Park, Soo Jin Park, Eun Ji Lee, Hee Seung Kim, Sunju Kim, Chungsik Yoon

{"title":"Airborne and surface contamination after rotational intraperitoneal pressurized aerosol chemotherapy using cisplatin.","authors":"Wongeon Jung, Mijin Park, Soo Jin Park, Eun Ji Lee, Hee Seung Kim, Sunju Kim, Chungsik Yoon","doi":"10.3802/jgo.2025.36.e12","DOIUrl":"10.3802/jgo.2025.36.e12","url":null,"abstract":"Objective: We evaluated the occupational exposure levels of healthcare workers while conducting rotational pressurized intraperitoneal aerosol chemotherapy (RIPAC) using cisplatin in a large animal model.Methods: We performed RIPAC using cisplatin in 6 female pigs and collected surface and air samples during the procedure. Surface samples were obtained from RIPAC devices and personal protective equipment (PPE) by wiping, and air samples were collected around the operating table. All samples were analyzed by inductively coupled plasma-mass spectrometry to detect platinum.Results: Among all surface samples (n=44), platinum was detected in 41 samples (93.2%) but not in all air samples (n=16). Among samples collected from RIPAC devices (n=23), minimum and maximum cisplatin levels of 0.08 and 235.09 ng/cm² were detected, mainly because of direct aerosol exposure in the abdominal cavity. Among samples collected from healthcare workers' PPE (n=21), 18 samples (85.7%) showed contamination levels below the detection limit, with a maximum of 0.23 ng/cm². There was no significant contamination among samples collected from masks, shoes, or gloves.Conclusion: During the RIPAC procedures, there is a potential risk of dermal exposure, as platinum, a surrogate material for cisplatin, was detected at low concentration levels in some surface samples. However, the respiratory exposure risk was not identified, as platinum was not detected in the airborne samples in this study.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e12"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141317495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas. 有选择性地利用循环肿瘤 DNA 检测对子宫内膜癌和卵巢癌进行疾病监测。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2025-01-01 Epub Date: 2024-06-17 DOI: 10.3802/jgo.2025.36.e5

Amy Jamieson, Melissa K McConechy, Amy Lum, Janine Senz, Tanner Dowhy, David G Huntsman, Jessica N McAlpine

{"title":"Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas.","authors":"Amy Jamieson, Melissa K McConechy, Amy Lum, Janine Senz, Tanner Dowhy, David G Huntsman, Jessica N McAlpine","doi":"10.3802/jgo.2025.36.e5","DOIUrl":"10.3802/jgo.2025.36.e5","url":null,"abstract":"Objective: Biomarkers reflecting real-time response to therapy and recurrence are lacking. We assessed the clinical value of detecting cell-free circulating tumor DNA (ctDNA) mutations in endometrial cancer (EC) and ovarian cancer (OC) patients.Methods: EC/OC patients undergoing primary surgery were consented for tissue banking and 2-year serial blood draws. Tumor tissue DNA and plasma ctDNA underwent next generation sequencing using a targeted gene panel for somatic mutations.Results: Of 44 patients (24 EC, 17 OC, 2 synchronous endometrial and ovarian carcinomas [SEOC] and 1 endocervical adenocarcinoma [EA]) at least one somatic mutation was identified in tumor tissue in 40 (91%, 20/24 EC, all OC/SEOC/EA), and in preoperative plasma ctDNA in 12 (27%) patients (6/24 [25%] EC and 6/17 [35%] OC). Detection of preoperative ctDNA mutations was associated with advanced stage, higher preoperative CA125, and subsequent disease recurrence. In 5/12 (42%) patients with preoperative ctDNA mutations, examination/imaging suggested clinical stage I however final pathology revealed stage II/III. In 11 patients where serial timepoints were assessed during treatment for ctDNA and CA125, ctDNA clearance preceded normalization of CA125. Thirteen patients developed recurrent disease (4 EC, 8 OC, 1 EA); 8 in whom ctDNA mutations were detected postoperatively, and 4 followed through time of recurrence with ctDNA mutations identified 2-5 months prior to clinical/radiologic/biomarker progression in 3.Conclusion: ctDNA can reflect larger tumor volume/metastases, treatment response and subsequent disease recurrence in EC and OC. Careful patient selection is critical to direct resources to patients most likely to benefit, considering disease burden and risk group.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e5"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic impact of the number of resected pelvic nodes in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis. 切除盆腔结节数量对子宫内膜癌预后的影响：日本妇科肿瘤集团研究 JGOG2043 的事后分析。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2025-01-01 Epub Date: 2024-06-03 DOI: 10.3802/jgo.2025.36.e3

Yosuke Konno, Michinori Mayama, Kazuhiro Takehara, Yoshihito Yokoyama, Jiro Suzuki, Nobuyuki Susumu, Kenichi Harano, Satoshi Nakagawa, Toru Nakanishi, Wataru Yamagami, Kosuke Yoshihara, Hiroyuki Nomura, Aikou Okamoto, Daisuke Aoki, Hidemichi Watari

{"title":"Prognostic impact of the number of resected pelvic nodes in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis.","authors":"Yosuke Konno, Michinori Mayama, Kazuhiro Takehara, Yoshihito Yokoyama, Jiro Suzuki, Nobuyuki Susumu, Kenichi Harano, Satoshi Nakagawa, Toru Nakanishi, Wataru Yamagami, Kosuke Yoshihara, Hiroyuki Nomura, Aikou Okamoto, Daisuke Aoki, Hidemichi Watari","doi":"10.3802/jgo.2025.36.e3","DOIUrl":"10.3802/jgo.2025.36.e3","url":null,"abstract":"Objective: This study aimed to determine whether the number of resected pelvic lymph nodes (PLNs) affects the prognosis of endometrial cancer (EC) patients at post-operative risk of recurrence.Methods: JGOG2043 was a randomized controlled trial to assess the efficacy of three chemotherapeutic regimens as adjuvant therapy in EC patients with post-operative recurrent risk. A retrospective analysis was conducted on 250 patients who underwent pelvic lymphadenectomy alone in JGOG2043. The number of resected and positive nodes and other clinicopathologic risk factors for survival were retrieved.Results: There were 83 patients in the group with less than 20 PLNs removed (group A), while 167 patients had 20 or more PLNs removed (group B). There was no significant difference in patients' backgrounds between the two groups, and the rate of lymph node metastasis was not significantly different. There was a trend toward fewer pelvic recurrences in group B compared with group A (3.5% vs. 9.6%; p=0.050). Although Kaplan-Meier analysis showed no statistically significant difference in survival rates between the two groups (5-year overall survival [OS]=90.3% vs. 84.3%; p=0.199), multivariate analysis revealed that resection of 20 or more nodes is one of the independent prognostic factors (hazard ratio=0.49; 95% confidence interval=0.24-0.99; p=0.048), as well as surgical stage, high-risk histology, and advanced age for OS.Conclusion: Resection of 20 or more PLNs was associated with improved pelvic control and better survival outcomes in EC patients at risk of recurrence who underwent pelvic lymphadenectomy alone and were treated with adjuvant chemotherapy.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e3"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0